Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Guillermo Garcia-Manero, Lalit Saini, Amer Zeidan, Abdulraheem Yacoub, Lori Maness, Elie Traer, James Foran, Sanjay Mohan, Michael Lübbert, Tom Lodewyck, Blanca Xicoy, Harshad Amin, Kimo Bachiashvili, Habte Yimer, Nancy Zhu, Haifa Kathrin Al-Ali, Patricia Font Lopez, Guillermo Sanz, Valeria Santini, Jesús Berdeja, Victor Priego, Olatoyosi Odenike, Bert Heyrman, David Valcarcel, Yubing Wan, Winny Chan, Aram Oganesian, Yuri Sano, Harold Keer, Elizabeth Griffiths
Institutions: The University of Texas MD Anderson Cancer Center, London Health Sciences Centre, Yale University, University of Kansas Medical Center, Nebraska Medical Center, University of Nebraska Medical Center, Oregon Health & Science University, OHSU Knight Cancer Institute, Mayo Clinic Comprehensive Cancer Center (Florida), Vanderbilt-Ingram Cancer Center, University of Freiburg, University Medical Center Freiburg, AZ Sint-Jan, Universitat Autònoma de Barcelona, Josep Carreras Leukaemia Research Institute, Hospital Universitari Germans Trias i Pujol, BRCR Global (United States), University of Alabama at Birmingham, University of Alberta, Martin Luther University Halle-Wittenberg, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital Universitari i Politècnic La Fe, University of Florence, Tennessee Oncology, Center for Cancers and Blood Disorders, University of Chicago, Vall d'Hebron Hospital Universitari, Taiho Oncology (United States), Roswell Park Comprehensive Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417011663